Results 61 to 70 of about 66,840 (318)
South African Medical Journal, 2022 Background. Ivermectin is an antiparasitic drug that has shown in vitro activity against COVID‑19. Clinical studies supporting ivermectin for COVID‑19 prevention and treatment are conflicting, with important limitations. Public support for ivermectin is
V Pillay-Fuentes Lorente +8 more
doaj +1 more source
Ivermectin for onchocercal eye disease (river blindness).
, 2012 BACKGROUND: It is believed that ivermectin (a microfilaricide) could prevent blindness due to onchocerciasis. However, when given to everyone in communities where onchocerciasis is common, the effects of ivermectin on lesions affecting the eye are ...
Ejere, Henry OD +3 more
core +1 more source
A brief overview of current drug repurposing approaches for COVID-19 management [PDF]
, 2020 This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares +1 more
core +2 more sources
Journal of Medical Virology, 2021 This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment.
H. Elalfy +14 more
semanticscholar +1 more source
Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
Infectious Diseases of Poverty, 2019 Background There is accumulating evidence supporting the use of ivermectin as a malaria control tool. Recent findings from the repeat ivermectin mass drug administrations for control of malaria trial demonstrated a reduced incidence of malaria in ...
Joseph Nelson Siewe Fodjo +5 more
doaj +1 more source
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
In Vivo, 2020 Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone ...
S. Lehrer, P. Rheinstein
semanticscholar +1 more source
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Open Forum Infectious Diseases, 2021 Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations.
A. Hill +9 more
semanticscholar +1 more source
The Population Biology and Transmission Dynamics of Loa loa [PDF]
, 2017 Endemic to Central Africa, loiasis – or African eye worm (caused by the filarial nematode Loa loa) – affects more than 10 million people. Despite causing ocular and systemic symptoms, it has typically been considered a benign condition, only of public ...
Basáñez, M-G +5 more
core +1 more source
Molecular mechanisms of Cys-loop ion channel receptor modulation by ivermectin
Frontiers in Molecular Neuroscience, 2012 Ivermectin is a gold standard anthelmintic drug that works by potently depressing neuronal activity and muscular contractility in arthropods and nematodes. At the molecular level, ivermectin activates inhibitory glutamate-gated chloride channels (GluClRs)
Timothy eLynagh, Joe eLynch
doaj +1 more source
Reviews in Medical Virology, 2021 Ivermectin is an FDA‐approved drug for a parasitic disease that has broad antiviral activity. This study aims to analyse the efficacy of ivermectin in improving the Covid‐19 outcomes.
T. Hariyanto +4 more
semanticscholar +1 more source